Cure MSA

Country specific patient information

Istituto Carlo Besta

Principal investigator:

Prof. Alberto Albanese, MD

Istituto Clinico Humanitas,
Via Alessandro Manzoni, 56
I-20089 Rozzano Milano
alberto.albanese(at)unicatt.it

Expertise of the participating organization:

The group has been involved for many years in the study of multiple system atrophy with a main emphasis on the clinical features and the criteria for a clinical diagnosis. The patients are followed-up using a computerised database. The centre is a referral for many patients who seek to receive an efficacious treatment that is not yet available.

The clinical activities are performed at the National Neurological Institute (www.istituto-besta.it) a tertiary referral centre for neurological diseases that collects patients from all over Italy (half of the patients seen are from outside Lombardy).
Prof. Alberto Albanese is the department head, Dr. Francesco Carella is the study coordinator.


Publications relevant to the EMSA-SG:

Albanese A. Can falls be prevented in Parkinson's disease? J Neurol Neurosurg Psychiatry 2007; 78: 661.

 

Del Sorbo F, Elia AE, De Joanna G, Romito LM, Garavaglia B, Albanese A. Normal cardiovascular reflex testing in patients with parkin disease. Mov Disord 2007; 22: 528-32. 

 

Albanese A, Valente EM, Romito LM, Bellacchio E, Elia AE, Dallapiccola B. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 2005; 64: 1958-60. 

 

Rossi G, Gasparoli E, Pasquali C, Di Fede G, Testa D, Albanese A, et al. Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. Ann Neurol 2004; 55: 448. 

 

Albanese A. Diagnostic criteria for Parkinson's disease. Neurol Sci 2003; 24 Suppl 1: S23-6. 

 

Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003; 98: 1439-40. 

 

Albanese A, Colosimo C. Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists. Acta Neurol Scand 2003; 107: 349-55. 

 

Soliveri P, Rossi G, Monza D, Tagliavini F, Piacentini S, Albanese A, et al. A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Arch Neurol 2003; 60: 1454-6. 

 

 

Istituti Clinici di Perfezionamento


Principal investigator:
Prof. Angelo Antonini, MD, PhD


Parkinson Institute
Istituti Clinici di Perfezionamento (ICP)
Via Bignami 1
I-20126 Milano

 

Publications relevant to the EMSA-SG:

Siri C, Duerr S, Canesi M, Delazer M, Esselink R, Bloem BR, Gurevich T, Balas M, Giladi N, Santacruz P, Marti F, Tolosa E, Rubino A, Meco G, Poewe W, Pezzoli G, Wenning G, Antonini A. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm (Vienna) 2013;120:613-618.

 

Pezzoli G, Tesei S, Canesi M, Sacilotto G, Vittorio M, Mizuno Y, Mochizuki H, Antonini A. The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. Clin Neurol Neurosurg 2010;112:65-67.

 

Cilia R, Marotta G, Benti R, Pezzoli G, Antonini A. Brain SPECT imaging in multiple system atrophy. J Neural Transm (Vienna) 2005;112:1635-1645.

 

Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, Meucci N, Canesi M, Mariani C, Pezzoli G, Gerundini P. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 2003;24:149-150.